Neuberger Berman Group LLC Sells 9,001,249 Shares of Pfizer Inc. (NYSE:PFE)

Neuberger Berman Group LLC lessened its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 64.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,945,893 shares of the biopharmaceutical company's stock after selling 9,001,249 shares during the quarter. Neuberger Berman Group LLC owned 0.09% of Pfizer worth $131,175,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. PSI Advisors LLC grew its position in Pfizer by 1.4% in the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock valued at $738,000 after acquiring an additional 385 shares during the last quarter. Patriot Financial Group Insurance Agency LLC grew its holdings in shares of Pfizer by 1.0% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock valued at $1,027,000 after purchasing an additional 391 shares during the last quarter. D Orazio & Associates Inc. increased its position in Pfizer by 5.5% during the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock worth $200,000 after purchasing an additional 391 shares in the last quarter. Lipe & Dalton lifted its stake in Pfizer by 17.7% in the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 400 shares during the last quarter. Finally, Oliver Luxxe Assets LLC boosted its position in Pfizer by 2.2% in the fourth quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock valued at $499,000 after buying an additional 401 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Remove Ads

Pfizer Stock Up 0.6 %

Pfizer stock traded up $0.14 during mid-day trading on Monday, reaching $22.05. The stock had a trading volume of 26,674,615 shares, compared to its average volume of 40,187,113. The firm has a market capitalization of $125.06 billion, a PE ratio of 15.64, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The stock's 50-day simple moving average is $25.25 and its 200-day simple moving average is $26.38. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter last year, the firm posted $0.10 EPS. Pfizer's revenue was up 24.7% compared to the same quarter last year. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on PFE. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. UBS Group cut their price target on Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a research note on Tuesday, April 8th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. Finally, Citigroup restated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $31.07.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.